This page shows the latest amyloidosis news and features for those working in and with pharma, biotech and healthcare.
The protein, which is called transthyretin (TTR), can become abnormal in ATTR amyloidosis and break apart into smaller pieces (amyloid). ... for standard of care Onpattro (patisiran), Alnylam’s earlier RNAi ATTRv amyloidosis therapy that is
The liver-targeted antisense therapy is in phase 3 trials for the treatment of transthyretin amyloidosis, a systemic, progressive and fatal condition. ... Eplontersen has the potential to halt the progression of TTR-mediated amyloidosis irrespective of
In addition to $13bn in sales from Comirnaty, anticoagulant Eliquis (apixaban) grew by 19% to $1.3bn, amyloidosis therapy Vyndaqel/Vyndamax (tafamidis) was up by 42% to $502m and Inlyta increased
$350m. CAEL-101 is a potential first-in-class monoclonal antibody for the treatment of light chain (AL) amyloidosis. ... Standard treatment for AL amyloidosis is chemotherapy combined with thalidomide and/or steroids, which is effective but can kill the
Initially, Novo will focus on the clinical development of Prothena’s antibody PRX004 in ATTR cardiomyopathy, an underdiagnosed and potentially fatal form of ATTR amyloidosis. ... Elsewhere in the therapy area is Alnylam’s Onpattro (patisiran), which
Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar pricing strategy.
More from news
Approximately 4 fully matching, plus 40 partially matching documents found.
Remote monitoring in practice. A prominent example of effective remote monitoring can be found in trials for ATTR cardiac amyloidosis (ATTR-CM).
Onpattro was approved to treat adults with the. destruction of nerves that results from a rare disease, hereditary transthyretin- mediated (hATTR) amyloidosis, and was launched with a $450, 000 per year ... pipeline. The company submitted its lumasiran
The drug is licensed to treat to adults with stage 1 or 2 polyneuropathy, the destruction of nerves that results from hereditary transthyretin- mediated (hATTR) amyloidosis, a rare, rapidly progressive, fatal ... The company is working with patient
spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis). ... The drug is to be granted marketing approval by the European Medicines Agency for the treatment of
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
What is Light-chain (AL) Amyloidosis? Amyloidosis is a group of rare, serious conditions caused by the abnormal folding of amyloid proteins that build up in tissue throughout the body. ... enhance recognition of AL Amyloidosis itself and the therapies
Three monoclonal antibodies were presented on the last day of ASCO - two in multiple myeloma and one in amyloidosis.
What does the future hold for Light-chain Amyloidosis?.
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...